Dr. McArthur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Road 3rd floor Nc3500
Dallas, TX 75390Phone+1 214-645-4673
Summary
- Dr. Heather McArthur is an oncologist in Dallas, TX and is affiliated with University of Texas Southwestern Medical Center. She received her medical degree from University of Toronto Faculty of Medicine, a fellowship degree from the British Columbia Cancer Agency, a Master of Public Health degree from Harvard University and has been in practice 16 years. She specializes in breast cancer and is experienced in breast cancer, oncology, and internal medicine. She has more than 90 publications and over 500 citings.
Education & Training
Memorial-Sloan Kettering Cancer CenterAdvanced Clinical Research Fellowship, Breast Oncology, 2006 - 2010- Harvard UniversityMPH, Clinical Effectiveness, 2006 - 2008
- British Columbia Cancer Agency/University of British ColumbiaMedical Oncology Fellowship, 2004 - 2006
- University of CalgaryInternal Medicine Residency, 2001 - 2004
University of Toronto Faculty of MedicineClass of 2001
Certifications & Licensure
TX State Medical License 2022 - 2026
CA State Medical License 2016 - 2022
NY State Medical License 2009 - 2019
Clinical Trials
- Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer Start of enrollment: 2011 Dec 01
- Breast Cancer Study of Preoperative Pembrolizumab + Radiation Start of enrollment: 2017 Dec 22
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer Start of enrollment: 2019 Nov 12
- Join now to see all
Publications & Presentations
PubMed
- Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for en...Manali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, Gerald Li, Takara Scott
Breast Cancer Research and Treatment. 2024-10-01 - Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive ...Manali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, Gerald Li, Takara Scott
Breast Cancer Research and Treatment. 2024-10-01 - PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative ...Alice Y Ho, Stephen Shiao, Samantha A Kobald, Jonathan Chen, Dan G Duda
Journal of Clinical Oncology. 2024-09-19
Lectures
- ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.2019 ASCO Annual Meeting - 6/1/2019
- A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Fighting Triple-Negative Breast Cancer Is Hard, but Not ImpossibleOctober 25th, 2024- Breast Cancer Mortality Is down but Cases Are up. North Texas Health Experts Weigh InOctober 7th, 2024
- Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast CancerJune 1st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
